Greenwich LifeSciences is a clinical-stage biopharmaceutical company developing GP2, an immunotherapy to prevent breast cancer recurrences in patients who have undergone surgery. The company targets patients with HER2/neu-positive breast cancer who have completed neoadjuvant and adjuvant trastuzumab-based treatments.
Some research tools need a free Smallfolk account or a Smallfolk Pro plan.